Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hemagglutinin 5 (H5) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hemagglutinin 5 (H5) - Pipeline Review, H1 2016', provides in depth analysis on Hemagglutinin 5 (H5) targeted pipeline therapeutics. The report provides comprehensive information on the Hemagglutinin 5 (H5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Hemagglutinin 5 (H5) - The report reviews Hemagglutinin 5 (H5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Hemagglutinin 5 (H5) targeted therapeutics and enlists all their major and minor projects - The report assesses Hemagglutinin 5 (H5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Hemagglutinin 5 (H5) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Hemagglutinin 5 (H5) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hemagglutinin 5 (H5) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hemagglutinin 5 (H5) Overview 6 Therapeutics Development 7 Hemagglutinin 5 (H5) - Products under Development by Stage of Development 7 Hemagglutinin 5 (H5) - Products under Development by Therapy Area 8 Hemagglutinin 5 (H5) - Products under Development by Indication 9 Hemagglutinin 5 (H5) - Pipeline Products Glance 10 Early Stage Products 10 Hemagglutinin 5 (H5) - Products under Development by Companies 11 Hemagglutinin 5 (H5) - Products under Development by Universities/Institutes 13 Hemagglutinin 5 (H5) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Hemagglutinin 5 (H5) - Companies Involved in Therapeutics Development 21 Altravax, Inc. 21 Ilyang Pharmaceutical Co., Ltd 22 Inovio Pharmaceuticals, Inc. 23 NewLink Genetics Corporation 24 Vaxine Pty Ltd 25 Hemagglutinin 5 (H5) - Drug Profiles 26 DPC-005 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 influenza [strain A/H5N1] (split virion) vaccine - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 influenza [strain A/H5N1] vaccine - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 influenza [strain A/H5N1] vaccine - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 influenza vaccine 2 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 INO-3510 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 IY-7640 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Monoclonal Antibodies to Inhibit H5 HA and H7 HA for Avian Infection - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 VGX-3400X - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Hemagglutinin 5 (H5) - Dormant Projects 36 Hemagglutinin 5 (H5) - Featured News & Press Releases 37 Sep 06, 2012: Inovio Pharma Takes Major Stride Toward Universal Influenza Vaccine 37 Jul 10, 2012: Inovio Pharma Initiates Phase I H1N1 Universal Influenza Vaccine Clinical Trial 38 May 16, 2012: Inovio Pharma's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial 39 May 16, 2012: Inovio's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial 41 Mar 26, 2012: Inovio Receives US Patent For SynCon H1N1 Influenza Universal Vaccine 42 Jan 31, 2012: Inovio Pharmaceuticals Moves Closer To Universal Influenza Vaccine By Demonstrating Protective Immune Responses Against Multiple H3N2 And Type B Strains In Animal Studies 43 Nov 17, 2011: Inovio's Synthetic Avian Flu Vaccine Demonstrates Inhibition Of Multiple H5N1 Strains In Phase I Trial 44 Jul 14, 2011: Inovio Demonstrates Positive Immune Responses In Phase I Clinical Trial of SynCon H5N1 Influenza Vaccine 46 Jul 14, 2011: Inovio Launches Multi-Subtype Influenza Vaccine Phase I Trial 47 Sep 30, 2010: About Inovio's SynCon Universal Influenza Vaccines 48 Sep 30, 2010: Inovio's SynCon Universal Influenza DNA Vaccine Technology Recognized With NIH Director's Transformative Research Award 48 Jun 15, 2010: Inovio Immunizes First Subject In US Influenza DNA Vaccine Clinical Trial 49 Mar 02, 2010: Inovio Receives Korean Approval To Begin Clinical Trials Of H5N1 Avian Influenza DNA Vaccine 49 Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies 50 Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Altravax, Inc., H1 2016 21 Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2016 22 Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 23 Pipeline by NewLink Genetics Corporation, H1 2016 24 Pipeline by Vaxine Pty Ltd, H1 2016 25 Dormant Projects, H1 2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.